Analysis of treatment outcomes for primary tonsillar lymphoma.
- Author:
Yun Hee LEE
1
;
Seok Goo CHO
;
Seung Eun JUNG
;
Sung Hoon KIM
;
Joo Hyun O
;
Gyeong Sin PARK
;
Suk Woo YANG
;
In Seok LEE
;
Chin Kook RHEE
;
Byung Ock CHOI
Author Information
- Publication Type:Original Article
- Keywords: Palatine Tonsil; Non-Hodgkin lymphoma; Radiotherapy
- MeSH: Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Therapy; Follow-Up Studies; Humans; Lymphoma*; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Palatine Tonsil; Prednisone; Prognosis; Radiotherapy; Rituximab; Vincristine
- From:Radiation Oncology Journal 2016;34(4):273-279
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Although each Waldeyer’s ring sub-site is considered an independent prognostic factor, few studies have assessed the prognosis and treatment of tonsillar lymphoma. Treatment outcomes were analyzed in patients with primary tonsillar lymphoma who were treated with chemotherapy and radiotherapy (RT). MATERIALS AND METHODS: Nineteen patients with diffuse large B-cell lymphoma were evaluated, with a median follow-up of 53 months. Age, sex, and histology, amongst other factors, were reviewed. Progression-free survival (PFS) and overall survival (OS) rates were analyzed. RESULTS: Most patients had Ann Arbor stage I-II (94.7%), IPI score of 0 (89.5%), and complete remission after chemotherapy (89.5%). The 5-year PFS and OS rates were 74.6% and 80%, respectively. In univariate analysis, the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen resulted in a better PFS than the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen (88.9% vs. 50.0%; p = 0.053). RT dose was related to the survival outcome (p = 0.010 for PFS, p = 0.044 for OS). Patients were classified into the CHOP + RT (>40 Gy) group and R-CHOP + RT (≤40 Gy) group. The 5-year PFS rates were 50% in the CHOP + RT group, and 100 % in the R-CHOP + RT group (p = 0.018). The 5-year OS rates were 66.7% and 100%, respectively (p = 0.087). CONCLUSION: Primary tonsillar lymphoma patients typically have favorable outcomes. Chemotherapy (R-CHOP) combined with relatively lower dose consolidative RT may be safe and effective for primary tonsillar lymphoma.
